Halozyme Therapeutics (NASDAQ:HALO) shareholder returns have been stellar, earning 193% in 5 years [Yahoo! Finance]
Halozyme Therapeutics, Inc. (HALO)
Last halozyme therapeutics, inc. earnings: 2/24 04:02 pm
Check Earnings Report
US:NASDAQ Investor Relations:
halozyme.com/investors/default.aspx
Company Research
Source: Yahoo! Finance
But on the bright side, if you buy shares in a high quality company at the right price, you can gain well over 100%. For example, the Halozyme Therapeutics, Inc. NASDAQ:HALO ) share price has soared 193% in the last half decade. Most would be very happy with that. On top of that, the share price is up 29% in about a quarter. The past week has proven to be lucrative for Halozyme Therapeutics investors, so let's see if fundamentals drove the company's five-year performance. See our latest analysis for Halozyme Therapeutics To quote Buffett, 'Ships will sail around the world but the Flat Earth Society will flourish. There will continue to be wide discrepancies between price and value in the marketplace...' By comparing earnings per share (EPS) and share price changes over time, we can get a feel for how investor attitudes to a company have morphed over time. During the last half decade, Halozyme Therapeutics became profitable. Sometimes, the start of profitability is a major infl
Show less
Read more
Impact Snapshot
Event Time:
HALO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
HALO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
HALO alerts
High impacting Halozyme Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
HALO
News
- Halozyme cut to Neutral at J.P. Morgan on valuation [Seeking Alpha]Seeking Alpha
- Halozyme Therapeutics, Inc. (NASDAQ: HALO) was downgraded by analysts at JPMorgan Chase & Co. from an "overweight" rating to a "neutral" rating. They now have a $57.00 price target on the stock, up previously from $52.00.MarketBeat
- Kaskela Law LLC Announces Shareholder Investigation of Halozyme Therapeutics, Inc. (HALO) and Encourages Investors to Contact the FirmBusiness Wire
- FDA approves Roche's Ocrevus Zunovo with Halozyme Enhanze delivery tech [Yahoo! Finance]Yahoo! Finance
- Roche Gets FDA Approval for Subcutaneous Formulation of Tecentriq [Yahoo! Finance]Yahoo! Finance
HALO
Earnings
- 8/6/24 - Beat
HALO
Sec Filings
- 9/26/24 - Form 4
- 9/26/24 - Form 144
- 9/25/24 - Form 144
- HALO's page on the SEC website